Trexquant Investment LP Editas Medicine, Inc. Transaction History

Trexquant Investment LP

$7.59 Billion
Q3 2024

A detailed history of Trexquant Investment LP transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Trexquant Investment LP holds 27,446 shares of EDIT stock, worth $65,321. This represents 0.0% of its overall portfolio holdings.

Number of Shares

27,446

Previous 472,715 94.19%

Holding current value

$65,321

Previous $2.21 Million 95.79%

% of portfolio

0.0%

Previous 0.03%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$3.39 - $5.96 $1.51 Million - $2.65 Million	-445,269 Reduced 94.19%	27,446 $93,000
Q2 2024 Aug 13, 2024	BUY	$4.67 - $7.28 $1.28 Million - $1.99 Million	273,510 Added 137.3%	472,715 $2.21 Million
Q1 2024 May 14, 2024	SELL	$7.03 - $11.07 $299,119 - $471,017	-42,549 Reduced 17.6%	199,205 $1.48 Million
Q4 2023 Feb 09, 2024	BUY	$6.25 - $11.11 $339,031 - $602,661	54,245 Added 28.93%	241,754 $2.45 Million
Q3 2023 Nov 13, 2023	BUY	$6.92 - $9.31 $745,809 - $1 Million	107,776 Added 135.17%	187,509 $1.46 Million
Q2 2023 Aug 11, 2023	BUY	$6.36 - $11.47 $357,711 - $645,118	56,244 Added 239.45%	79,733 $656,000
Q1 2023 May 15, 2023	BUY	$7.03 - $11.53 $165,127 - $270,828	23,489 New	23,489 $170,000
Q3 2022 Nov 14, 2022	BUY	$12.16 - $19.42 $607,732 - $970,572	49,978 New	49,978 $612,000
Q1 2022 May 13, 2022	SELL	$14.08 - $27.63 $248,286 - $487,227	-17,634 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$26.55 - $40.57 $468,182 - $715,411	17,634 New	17,634 $468,000
Q2 2021 Aug 12, 2021	SELL	$31.29 - $56.64 $828,152 - $1.5 Million	-26,467 Closed	0 $0
Q1 2021 May 13, 2021	BUY	$39.71 - $90.58 $1.05 Million - $2.4 Million	26,467 New	26,467 $1.11 Million
Q4 2020 Feb 11, 2021	SELL	$27.07 - $84.35 $254,295 - $792,383	-9,394 Closed	0 $0
Q3 2020 Nov 06, 2020	BUY	$28.06 - $37.16 $39,312 - $52,061	1,401 Added 17.53%	9,394 $264,000
Q2 2020 Aug 07, 2020	BUY	$18.5 - $34.34 $147,870 - $274,479	7,993 New	7,993 $236,000
Q2 2019 Aug 09, 2019	SELL	$20.48 - $27.76 $312,156 - $423,117	-15,242 Closed	0 $0
Q1 2019 May 13, 2019	SELL	$19.43 - $26.41 $1.58 Million - $2.14 Million	-81,169 Reduced 84.19%	15,242 $373,000
Q4 2018 Feb 13, 2019	BUY	$18.19 - $31.79 $1.48 Million - $2.58 Million	81,311 Added 538.48%	96,411 $2.19 Million
Q3 2018 Nov 09, 2018	BUY	$27.65 - $38.39 $417,515 - $579,689	15,100 New	15,100 $480,000
Q2 2018 Aug 07, 2018	SELL	$31.4 - $41.01 $1.52 Million - $1.98 Million	-48,265 Closed	0 $0
Q1 2018 May 03, 2018	BUY	$29.84 - $44.08 $1.44 Million - $2.13 Million	48,265 New	48,265 $1.6 Million
Q4 2017 Feb 09, 2018	SELL	$21.89 - $31.34 $428,080 - $612,885	-19,556 Closed	0 $0
Q3 2017 Nov 09, 2017	BUY	$15.81 - $24.01 $309,180 - $469,539	19,556	19,556 $470,000

Others Institutions Holding EDIT

# of Institutions

248

Shares Held

57M

Call Options Held

410K

Put Options Held

394K

View Full List

About Editas Medicine, Inc.

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $164M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

More about EDIT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Trexquant Investment LP, based on Form 13F filings with the SEC.

News

Stay updated on Trexquant Investment LP with notifications on news.

Account

Trexquant Investment LP Editas Medicine, Inc. Transaction History